NTLA Intellia Therapeutics Inc Gross Profit Rate

Official company branding of Intellia Corp (NTLA)

Intellia Therapeutics (NTLA) offsets its high R&D expenditures through alliances with industry behemoths. The production margin chart reflects current cost efficiency, where the latest parameter stands at 76.90. A patent shield in the CRISPR field protects the business from dumping, while a future monopolist status in treating genetic pathologies will provide the company with the pricing power to set premium prices for its therapies.

Intellia Corp (NTLA) Gross Profitability: for the period 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for Intellia Corp (NTLA)

- stock value and consensus price forecast:
Summary company analysis:Intellia Therapeutics, Inc. - NTLA
Signature product of Intellia

Gross margin measures operational efficiency by determining the portion of revenue remaining after direct production costs, allowing investors to assess the business's actual margin of safety. The gross profit margin trend reflects the ability of Intellia Therapeutics (NTLA) to monetize unique CRISPR genome editing methods, transforming an innovative DNA correction ecosystem into a sustainable financial foundation for the medicine of the future.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|Stoke Therapeutics Inc (STOK) - Return on Sales by Gross Profit|Gross Margin BLFS|Gross Profitability WVE (Wave Life Sciences Corp)|Gross Profitability Maze Therapeutics MAZE|Gross Profit Rate SION|PRME - Gross Profitability|Return on Sales by Gross Profit Taysha TSHA|QURE: Gross Margin|Return on Gross Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability